Milestones and announcements, newest first.
A peer-reviewed paper describes the production and characterization of rNGFSP, the fusion immunogen that elicits dual anti-NGF and anti-Substance P antibodies.
Read more ↗ November 2025Athos will use its AI-driven omics platform to analyze plasma samples from Xeptiva’s trial in dogs with osteoarthritis pain, looking for biomarkers of response.
Read more ↗ November 2025Xeptiva was recognized among the finalists of the start-up category.
Read more ↗ December 2024Our co-founder and CIO received the second edition of the prize awarded by Uruguay’s Ministry of Education and Culture, recognizing his career in neuroscience.
Read more → October 2024The round was led by Zentynel Frontier Investments, with participation from iThink VC, ND Latam, Sergio Fogel, FEN Ventures and Uruguay Biotech Ventures.
Read more → July 2024Xeptiva now has its first GMP-quality vaccine, produced with academic and industrial partners after years of safety studies.
Read more → July 2024ANII approved funding for the national patent phases of Xeptiva’s products in Latin America, Asia and Europe.
Read more → December 2023The Institut Pasteur de Montevideo became a partner of Xeptiva, a milestone for the development of our technology.
Read more → June 2023Our CEO joins the program run by Endeavor, ANII and Ingenio to prepare start-ups for global markets.
Read more → May 2023Our CEO won WeXchange Chapter Uruguay and represented Xeptiva at the Women STEMpreneurs competition in Bogotá.
Read more → March 2023Funding for specialized staff, postgraduate internships, controlled clinical trials in dogs with osteoarthritis and training abroad.
Read more → December 2022Xeptiva signed a license to turn the technology patented at the Institute into marketable products.
Read more → March 2022An ANII academy–industry grant to validate the mechanism of action of our vaccine for chronic pain in companion animals.
Read more → September 2021The International Brain Research Organization recognized our CSO for his research on neurodegeneration and premature aging.
Read more →